Effects of arginine 10 to lysine substitution on ω‐conotoxin CVIE and CVIF block of Cav2.2 channels

No abstract is available for this paper.

• Publication year

  2014

• Venue

  British Journal of Pharmacology

• Publication date

  2014-07-01

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1111/bph.12686PMID 24628243PMCID PMC4080983
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Novel ω-conotoxins from C. catus reverse signs of mouse inflammatory pain after systemic administration

  2013cited by this paper
• Spinal actions of ω‐conotoxins, CVID, MVIIA and related peptides in a rat neuropathic pain model

  2013influential reference
• The Concise Guide to Pharmacology 2013/14: Ion Channels

  2013cited by this paper
• γ-Aminobutyric Acid Type B (GABAB) Receptor Expression Is Needed for Inhibition of N-type (Cav2.2) Calcium Channels by Analgesic α-Conotoxins*

  2012cited by this paper
• Targeting voltage‐gated calcium channels: developments in peptide and small‐molecule inhibitors for the treatment of neuropathic pain

  2012cited by this paper
• Analgesic conotoxins: block and G protein‐coupled receptor modulation of N‐type (CaV2.2) calcium channels

  2012influential reference
• Pharmacokinetic Analysis of Ziconotide (SNX‐111), an Intrathecal N‐Type Calcium Channel Blocking Analgesic, Delivered by Bolus and Infusion in the Dog

  2012influential reference
• Conus Venom Peptide Pharmacology

  2012influential reference
• Animal models of neuropathic pain

  2011cited by this paper
• Up-regulation of Cavβ3 Subunit in Primary Sensory Neurons Increases Voltage-activated Ca2+ Channel Activity and Nociceptive Input in Neuropathic Pain*

  2011cited by this paper
• Voltage-gated calcium channels.

  2011cited by this paper
• Drugs from slugs--past, present and future perspectives of omega-conotoxin research.

  2010cited by this paper
• Animal Research: Reporting In Vivo Experiments: The ARRIVE Guidelines

  2010cited by this paper
• Analgesic ω-Conotoxins CVIE and CVIF Selectively and Voltage-Dependently Block Recombinant and Native N-Type Calcium Channels

  2010influential reference
• Ziconotide for treatment of severe chronic pain.

  2010cited by this paper
• The engineering of an orally active conotoxin for the treatment of neuropathic pain.

  2010influential reference
• Guidelines for reporting experiments involving animals: the ARRIVE guidelines

  2010cited by this paper
• Ziconotide Combination Intrathecal Therapy: Rationale and Evidence

  2010cited by this paper
• In situ neutralization in Boc-chemistry solid phase peptide synthesis. Rapid, high yield assembly of difficult sequences.

  2009cited by this paper
• The role of binding kinetics in therapeutically useful drug action.

  2009cited by this paper
• Role of voltage-gated calcium channels in ascending pain pathways.

  2009cited by this paper
• Folding of Conotoxins: Formation of the Native Disulfide Bridges During Chemical Synthesis and Biosynthesis of Conus Peptides

  2008cited by this paper
• Ziconotide: an update and review

  2008cited by this paper
• Analgesic α-Conotoxins Vc1.1 and Rg1A Inhibit N-Type Calcium Channels in Rat Sensory Neurons via GABAB Receptor Activation

  2008cited by this paper
• Omega-conotoxin CVIB differentially inhibits native and recombinant N- and P/Q-type calcium channels.

  2007cited by this paper
• ω‐Conotoxin CVIB differentially inhibits native and recombinant N‐ and P/Q‐type calcium channels

  2007cited by this paper
• In Situ Neutralization in Boc-chemistry Solid Phase Peptide Synthesis

  2007cited by this paper
• Chemical modification of conotoxins to improve stability and activity.

  2007cited by this paper
• N-type calcium channel blockers: novel therapeutics for the treatment of pain.

  2006cited by this paper
• Label-free kinetic binding data as a decisive element in drug discovery

  2006cited by this paper
• Targeting N-type and T-type calcium channels for the treatment of pain.

  2006cited by this paper
• Targeting chronic and neuropathic pain: The N-type calcium channel comes of age

  2005cited by this paper
• International Union of Pharmacology. XLVIII. Nomenclature and Structure-Function Relationships of Voltage-Gated Calcium Channels

  2005cited by this paper
• Targeting Ca2+ channels to treat pain: T-type versus N-type.

  2004cited by this paper
• Conus venoms: a rich source of novel ion channel-targeted peptides.

  2004cited by this paper
• The α2δ Auxiliary Subunit Reduces Affinity of ω-Conotoxins for Recombinant N-type (Cav2.2) Calcium Channels*

  2004influential reference
• Ziconotide: neuronal calcium channel blocker for treating severe chronic pain.

  2004cited by this paper
• ω-Conotoxin CVID Inhibits a Pharmacologically Distinct Voltage-sensitive Calcium Channel Associated with Transmitter Release from Preganglionic Nerve Terminals*

  2003influential reference
• Pharmacokinetics and Pharmacodynamics of Intrathecal Ziconotide in Chronic Pain Patients

  2003influential reference
• Animal models of neuropathic pain.

  2003cited by this paper
• Actions of intrathecal omega-conotoxins CVID, GVIA, MVIIA, and morphine in acute and neuropathic pain in the rat.

  2002cited by this paper
• G Protein-Coupled Receptor Allosterism and Complexing

  2002cited by this paper
• Differential nociceptive responses in mice lacking the α1B subunit of N-type Ca2+ channels

  2001cited by this paper
• The cystine knot motif in toxins and implications for drug design.

  2001cited by this paper
• Differential nociceptive responses in mice lacking the alpha(1B) subunit of N-type Ca(2+) channels.

  2001cited by this paper
• Structural and dynamic characterization of omega-conotoxin MVIIA: the binding loop exhibits slow conformational exchange.

  2000cited by this paper
• Novel ω-Conotoxins from Conus catus Discriminate among Neuronal Calcium Channel Subtypes*

  2000cited by this paper
• Bioavailability of Ziconotide in brain: influx from blood, stability, and diffusion.

  2000influential reference
• Effects of chirality at Tyr13 on the structure-activity relationships of omega-conotoxins from Conus magus.

  1999cited by this paper
• Antagonist inhibition curves and the measurement of dissociation constants

  1997influential reference
• Preferential interaction of omega-conotoxins with inactivated N-type Ca2+ channels.

  1997cited by this paper
• Preferential Interaction of ω-Conotoxins with Inactivated N-type Ca2+ Channels

  1997influential reference
• MOLMOL: a program for display and analysis of macromolecular structures.

  1996cited by this paper
• 1H, 13C and 15N random coil NMR chemical shifts of the common amino acids. I. Investigations of nearest-neighbor effects

  1995cited by this paper
• Hydroxyl group of Tyr13 is essential for the activity of omega-conotoxin GVIA, a peptide toxin for N-type calcium channel.

  1994cited by this paper
• Calcium channel diversity and neurotransmitter release: the omega-conotoxins and omega-agatoxins.

  1994cited by this paper
• CALCIUM CHANNEL DIVERSITY AND NEUROTRANSMITTER RELEASE : THE OMEGA -CONOTOXINS AND OMEGA -AGATOXINS

  1994cited by this paper
• Calcium current variation between acutely isolated adult rat dorsal root ganglion neurons of different size.

  1992influential reference
• Pharmacokinetics and pharmacodynamics.

  1990influential reference

• PIONOCONUS: A PISCIVOROUS SUBGENUS OF CONUS GASTROPODS.

  2025cites this paper
• Pharmacological Classes of Conus Peptides Targeted to Calcium, Sodium, and Potassium Channels.

  2023cites this paper
• Fine-Tuning of Alkaline Residues on the Hydrophilic Face Provides a Non-toxic Cationic α-Helical Antimicrobial Peptide Against Antibiotic-Resistant ESKAPE Pathogens

  2021cites this paper
• Design, Synthesis, and Activity of an α-Conotoxin LtIA Fluorescent Analogue.

  2021cites this paper
• Discovery of Cyclotides from Australasian Plants

  2020cites this paper
• Therapeutic conotoxins: a US patent literature survey

  2015cites this paper
• Dicarba analogues of α-conotoxin RgIA. Structure, stability, and activity at potential pain targets.

  2014cites this paper